Skip to main content
Clinical Trials/NCT06077110
NCT06077110
Not yet recruiting
Not Applicable

Developing a Novel Precision Medicine Clinic to Drive Integration of Research Into Routine Healthcare: Precision Care Initiative

The University of New South Wales0 sites300 target enrollmentMay 2025
ConditionsCancer

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Cancer
Sponsor
The University of New South Wales
Enrollment
300
Primary Endpoint
Implementation Outcomes
Status
Not yet recruiting
Last Updated
last year

Overview

Brief Summary

The purpose of this study is to drive integration of precision medicine into routine oncology healthcare. It is hoped that this research will not only optimise the newly established Precision Care Clinic within the Prince of Wales Hospital, but also prime it for use within other health care sites. The multidisciplinary team will work to achieve the following three objectives:

  1. Co-design a Precision Care Clinic, its implementation platform and suite of outcome measures (Phase 1)
  2. Test the implementation-, service-, clinical, and cost-effectiveness of a Precision Care Clinic (Phase 2)
  3. Develop and pilot test a Precision Care scale-up model and toolkit (Phase 3)

A mixed-methods approach will be used to develop and evaluate an implementation platform to support the integration of precision medicine into the routine oncology setting at a single hospital site. In the first study phase, interviews and focus-groups will be used to develop the implementation platform, which involves a co-designed model of care supported by a Learning Health System. A Type II Hybrid effectiveness-implementation trial design will then be used to test the implementation, clinical, and cost-effectiveness of this novel model of care (phase 2). A combination of patient surveys and interviews will be used to measure patient-reported outcome measures (PROMs) and patient-reported experience measures (PREMs); stakeholder and patient interviews, surveys and focus-groups will be used to measure implementation outcomes; and cost data will be collected to inform an economic evaluation. These data will be collected at various stages of implementation to evaluate the effectiveness of the model of care over time. In the final study phase (phase 3), a scale-up model will be developed to support implementation of the new model of care across a wider range of clinical contexts. (Phase 3 will be detailed in a separate ethics amendment)

It is hoped that this research will not only optimise the newly established model of care within The Prince of Wales Hospital, but also prime it for use within other health care sites.

Registry
clinicaltrials.gov
Start Date
May 2025
End Date
March 2027
Last Updated
last year
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Natalie Taylor

Associate Professor

The University of New South Wales

Eligibility Criteria

Inclusion Criteria

  • have been referred to the Precision Care Clinic at POWH
  • speak English
  • are aged 18 years or over
  • are able to provide informed consent

Exclusion Criteria

  • aged under 18 years
  • non-English speaking
  • are unable to provide informed consent

Outcomes

Primary Outcomes

Implementation Outcomes

Time Frame: 3 months post-referral

sustainability \[industry engagement, grant support; clinical trial \& access options, research links (e.g., sub-studies) generated\]; qualitative measurement collected via interviews/focus groups/questionnaires

Service Outcomes

Time Frame: 3 months post-referral

Upstream indicators of clinical effectiveness that include: time from identification of germline research result to clinical confirmation; captured via audit data, measured in days; a smaller value indicates a preferred outcome.

Clinical Outcomes

Time Frame: 3 months post-referral

Patient reported experience of coordinated care; collected via questionnaires adapted for the precision medicine context; measured as ratings; a higher rating indicates a preferred outcome.

Secondary Outcomes

  • Clinical Outcome: Quality of life improvement (EQ-5D-5L, EuroQol-5 Dimension-5 Level)(3, 6, 9 months post-referral)
  • Clinical Outcome: Views and attitudes (patient-perceived benefits and drawbacks of process and care model), result return preferences, knowledge, perceived importance of genomic profiling(3, 6, 9 months post-referral)
  • Clinical Outcome: Psychological outcomes (e.g., anxiety and depression, coping with uncertainty)(3, 6, 9 months post-referral)
  • Clinical Outcome: Decisional outcomes (e.g., decisional regret regarding personalised treatment, decisional satisfaction)(3, 6, 9 months post-referral)

Similar Trials

Recruiting
Not Applicable
PRecision Oncology CUhk pRogrammE (PRO-CURE)Gastrointestinal Cancers
NCT04724070Brigette Ma200
Recruiting
Not Applicable
Prospective Clinical Validation of Next Generation Sequencing (NGS) and Patient-Derived Tumor Organoids (PDO) Guided Therapy in Patients With Advanced/ Inoperable Solid TumorsHepatocellular CarcinomaColorectal Cancer
NCT06077591Chinese University of Hong Kong40
Unknown
Phase 4
Implementing Precision Medicine Approaches to Guide Anti-platelet SelectionAcute Coronary Syndrome (ACS)STEMI - ST Elevation Myocardial Infarction (MI)NSTEMI - Non-ST Segment Elevation MIUnstable Angina (UA)
NCT04090281University of Southern California200
Recruiting
Phase 1
Ex Vivo Drug Sensitivity Testing and Multi-Omics ProfilingRecurrent Childhood Acute Myeloid LeukemiaRecurrent Childhood Acute Lymphoblastic LeukemiaRecurrent Childhood Large Cell LymphomaRefractory Childhood Acute Lymphoblastic LeukemiaRefractory Childhood Hodgkin LymphomaRefractory Childhood Malignant Germ Cell NeoplasmRecurrent Childhood Brain TumorRecurrent Childhood Brainstem GliomaRecurrent Childhood RhabdomyosarcomaRecurrent Childhood Soft Tissue SarcomaRecurrent Childhood EpendymomaRecurrent Childhood Lymphoblastic LymphomaRecurrent Childhood GliosarcomaRefractory Chronic Myelogenous Leukemia, BCR-ABL1 PositiveRefractory Childhood Malignant Solid NeoplasmRecurrent Childhood Malignant Solid NeoplasmRecurrent Childhood Malignant NeoplasmRefractory Childhood Malignant Neoplasm
NCT05857969Florida International University65
Not yet recruiting
Phase 2
Efficacy of Organoid-Based Chemotherapy Drug Precision Screening to Guide Treatment for Thyroid CancerLocally Advanced Thyroid Gland CarcinomaThyroid Cancer
NCT06713057West China Hospital20